VRTX — VERTEX PHARMACEUTICALS INC

Ownership history in Carmignac Gestion  ·  7 quarters on record

This page tracks every 13F SEC filing in which Carmignac Gestion reported a position in VERTEX PHARMACEUTICALS INC (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.63% (2024 Q3)
Avg. % of fund
1.32%
First filed
2024 Q2
Last filed
2025 Q4
Quarters held
7
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 191,571 +4,032 +2.1% 1.17% $86.9M $453.36
2025 Q3 REDUCED 187,539 -39,757 -17.5% 1.09% $73.5M $391.64
2025 Q2 ADDED 227,296 +100,342 +79.0% 1.56% $101.2M $445.20
2025 Q1 REDUCED 126,954 -70,512 -35.7% 1.01% $61.6M $484.82
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%
← Back to Carmignac Gestion Holdings